<DOC>
	<DOCNO>NCT01193907</DOCNO>
	<brief_summary>This trial aim evaluate safety immunogenicity profile three formulation Vi-CRM197 conjugate vaccine S. Typhi healthy human adult comparison currently license Vi polysaccharide vaccine</brief_summary>
	<brief_title>Safety Immunogenicity Three Formulations Vi-CRM197 Vaccine Against S. Typhi Adults ( 18-40 Years Old )</brief_title>
	<detailed_description />
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females age ≥18 ≤40 year . 2 . Individuals , nature study explain , give write consent accord local regulatory requirement . 3 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . 4 . Individuals negative urine screening test drug addition ( Opiate , Cocaine , Amph/Metamphetamine , Cannabinoides ) 5 . If woman , use birth control one month study start , negative pregnancy test willingness use birth control measure entire study duration . 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 2 . Individuals progressive severe neurological disorder , seizure disorder GuillainBarré syndrome . 3 . Individuals able understand follow require study procedure whole period study . 4 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study . 5 . Individuals know suspected HIV infection HIV related disease , history autoimmune disorder know suspected impairment /alteration immune system , immunosuppressive therapy include use systemic corticosteroid chronic use inhale highpotency corticosteroid within previous 30 day , chemotherapy treatment within past 6 month . 6 . Individuals know bleed diathesis , condition may associate prolonged bleeding time . 7 . Individuals serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . 8 . Individuals malignancy lymphoproliferative disorder . 9 . Individuals history allergy vaccine component . 10 . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . 11 . Individuals previously receive vaccine typhoid fever ( either oral live attenuate injectable vaccine ) . 12 . Individuals receive vaccine within 4 week prior enrolment study plan receive vaccine within 4 week study vaccine . 13 . Individuals receive blood , blood product and/or plasma derivative include parenteral immunoglobulin preparation past 12 week . 14 . Individuals part study personnel close family member personnel conduct study . 15 . Individuals body temperature &gt; 38.0 degree Celsius within 3 day intend study immunization . 16 . BMI &gt; 35 kg/m2 . 17 . Individuals history substance alcohol abuse within past 2 year . 18 . Women pregnant breastfeed childbearing age use birth control measure one month prior study start plan use acceptable birth control measure , duration study . 19 . Females history stillbirth , neonatal loss , previous infant anomaly . 20 . Individuals previously ascertain suspected disease cause S. Typhi . 21 . Individuals household contact with/and intimate exposure individual laboratory confirm S. Typhi . 22 . Any condition , opinion investigator may interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Typhoid fever</keyword>
	<keyword>Glycoconjugate vaccine</keyword>
	<keyword>Vi polysaccharide</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>